» Articles » PMID: 30025200

Hepatitis B Virus Infection and Risk of Non-alcoholic Fatty Liver Disease: A Population-based Cohort Study

Overview
Journal Liver Int
Specialty Gastroenterology
Date 2018 Jul 20
PMID 30025200
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Although non-alcoholic fatty liver disease (NAFLD) has been studied extensively, the potential risk factors for NAFLD among chronic hepatitis B (CHB) patients have not been fully known.

Methods: A population-based cohort of adult CHB patients without a history of alcohol drinking or NAFLD were recruited and followed up from October 2012 to January 2015 in Jiangsu province, China. Using Cox proportional hazards regression model, potential risk factors including viral and metabolic factors for NAFLD were evaluated.

Results: Two thousand three hundred and ninety-three adult CHB patients (mean age 50.7 ± 13.2 years) were included in the cohort. With 4429 person-years of follow-up, 283 individuals progressed to NAFLD with an incidence rate of 63.89/1000 person-years. Overweight and obese CHB patients had an increased risk of NAFLD (overweight adjusted hazard ratio [HR], 3.10; 95% CI, 2.29-4.18; obese HR, 8.52; 95%CI, 5.93-12.25) compared to normal weight carriers. The incidence of NAFLD was associated with concurrent type 2 diabetes mellitus (DM) (HR, 1.88; 95%CI, 1.15-3.08). However, no associations between viral factors with NAFLD incidence rate were identified. In a subgroup of participants with concurrent type 2 DM, detectable HBV DNA levels were negatively associated with the development of NAFLD (HR, 0.37; 95%CI, 0.14-0.98). There was super-multiplicative interaction between BMI and gender with respect to incidence of NAFLD, with an ROR of 2.08 (95%CI, 1.02-4.23).

Conclusion: Metabolic factors play an important role in the presence of NAFLD among Chinese CHB patients. However, viral replication factors are not related to NAFLD except among those with concurrent type 2 DM.

Citing Articles

Characterizing Unique Clinical and Virological Profiles in Concurrent Chronic Hepatitis B and Metabolic Dysfunction-Associated Liver Disease: Insights from a Population-Based Cohort Study.

Abu Baker F, Zeina A, Taher R, Mouch S, Israel A J Clin Med. 2024; 13(18).

PMID: 39337094 PMC: 11433373. DOI: 10.3390/jcm13185608.


Prevalence of nonalcoholic fatty liver disease in patients with hepatitis B: A meta-analysis.

Zhang L, Wu H, Qian Y, Xu H World J Clin Cases. 2024; 12(25):5749-5760.

PMID: 39247728 PMC: 11263053. DOI: 10.12998/wjcc.v12.i25.5749.


Metabolic disorders and hepatitis: Insights from a Mendelian randomization study.

Liang L, Liu X, Mao T, Su Q World J Gastrointest Surg. 2024; 16(6):1775-1790.

PMID: 38983337 PMC: 11230009. DOI: 10.4240/wjgs.v16.i6.1775.


Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients.

Zhao W, Liu Y, Zhang M, Cui Z, Qu Z, Li Y Front Med (Lausanne). 2024; 11:1399665.

PMID: 38895186 PMC: 11183333. DOI: 10.3389/fmed.2024.1399665.


Independent predictors for non-alcoholic fatty liver disease in patients with treatment-naïve chronic hepatitis B.

Tuncer G, Geyiktepe-Guclu C, Bayramlar O, Bozan B, Yucel C, Copur B Rev Assoc Med Bras (1992). 2024; 70(4):e20231036.

PMID: 38537007 PMC: 10962267. DOI: 10.1590/1806-9282.20231036.


References
1.
Zhu L, Zhai X, Zhu Y, Xu W, Bao C, Peng H . Evaluation of the impact of hepatitis B vaccination in adults in Jiangsu province, China. PLoS One. 2014; 9(6):e101501. PMC: 4076282. DOI: 10.1371/journal.pone.0101501. View

2.
Zhu L, Jiang J, Song C, Zou Y, Xu J, Liu H . [A cohort study of hepatitis B virus carriers progressing to chronic hepatitis in Jiangsu province, 2012-2014]. Zhonghua Liu Xing Bing Xue Za Zhi. 2017; 37(11):1463-1467. DOI: 10.3760/cma.j.issn.0254-6450.2016.11.006. View

3.
Cheng Y, Wang Y, Kao W, Chen P, Huo T, Huang Y . Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up. PLoS One. 2013; 8(8):e72049. PMC: 3750031. DOI: 10.1371/journal.pone.0072049. View

4.
Lee J, Kim K, Lee S, Yu E, Lim Y, Lee H . Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol. 2007; 47(2):239-44. DOI: 10.1016/j.jhep.2007.02.007. View

5.
Kim K, Shin H, Kim K, Choi H, Rhee S, Moon H . Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. Gastroenterology. 2007; 132(5):1955-67. DOI: 10.1053/j.gastro.2007.03.039. View